This inventor holds 1 USPTO granted patent. Top assignees: Centre National De La Recherche Scientifique, Ecole Nationale Superieure De Chimie De Montpellier, Universitè De Montpellier. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:



Years Active: 2022
Title: Sharon Wein-Grataud: Innovator in Nucleotide Analogues
Introduction
Sharon Wein-Grataud is a notable inventor based in Grabels, France. She has made significant contributions to the field of medicinal chemistry, particularly in the development of nucleotide analogues. Her work has implications for the treatment of diseases caused by specific infections.
Latest Patents
Sharon holds a patent for "Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicament." This patent encompasses chemical compounds that belong to the group of nucleotide analogues. Specifically, it discloses acylnucleoside phosphonate compounds, their method of preparation, and their use as medicaments, particularly for preventing and treating diseases caused by organisms that are auxotrophic for purines. Additionally, the patent includes pharmaceutical compositions containing such compounds. She has 1 patent to her name.
Career Highlights
Throughout her career, Sharon has worked with esteemed institutions such as Université de Montpellier and the Centre National de la Recherche Scientifique. Her research has focused on innovative solutions in the field of medicinal chemistry, contributing to advancements in therapeutic options.
Collaborations
Sharon has collaborated with notable colleagues, including Suzanne Peyrottes and Christian Perigaud. These partnerships have enriched her research and expanded the impact of her work in the scientific community.
Conclusion
Sharon Wein-Grataud's contributions to the field of nucleotide analogues highlight her role as an innovator in medicinal chemistry. Her patent and collaborations reflect her commitment to advancing medical science and improving treatment options for various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile